COMP <GO>
BDTX vs ENGN // OPERATING MARGIN
Black Diamond Therapeutics Inc. (NASDAQ) VS. enGene Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BDTX 4
— ENGN 0
■ METRIC PARITY
LAST: $1.86 (+1.64%) • MKT CAP: $106.9M
operating-margins
—
LAST: $1.53 (-3.16%) • MKT CAP: $102.5M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDTX VS. ENGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BDTX | ENGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.80% | -35.00% | +45.80 | BDTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 2/9 | +3.00 | BDTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 37.0 | +8.38 | BDTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.9M | $102.5M | $4.3M | BDTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BDTX REV | ENGN REV | BDTX GROSS % | ENGN GROSS % | BDTX FCF | ENGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | $29.6M | -$100.7M |
| FY 2024 | $0 | $0 | — | — | -$62.3M | -$49.2M |
| FY 2023 | $0 | $0 | — | — | -$66.7M | -$24.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDTX // BETA —
ENGN // BETA —